Halozyme Therapeutics (NASDAQ:HALO) is scheduled to post its quarterly earnings results after the market closes on Tuesday, August 6th. Analysts expect Halozyme Therapeutics to post earnings of ($0.17) per share for the quarter. Halozyme Therapeutics has set its FY 2019 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.
Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.01. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. The company had revenue of $56.95 million for the quarter, compared to analysts’ expectations of $67.80 million. During the same period in the prior year, the business earned ($0.19) EPS. The firm’s quarterly revenue was up 84.3% on a year-over-year basis. On average, analysts expect Halozyme Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Halozyme Therapeutics stock traded up $0.02 during midday trading on Tuesday, hitting $16.98. 16,993 shares of the company’s stock were exchanged, compared to its average volume of 650,354. The company has a current ratio of 2.95, a quick ratio of 2.72 and a debt-to-equity ratio of 0.07. Halozyme Therapeutics has a 12 month low of $13.24 and a 12 month high of $18.85. The business’s 50-day moving average price is $16.63. The firm has a market cap of $2.47 billion, a P/E ratio of -30.43 and a beta of 1.77.
Several research analysts have issued reports on the stock. BidaskClub upgraded shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. ValuEngine upgraded shares of Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Zacks Investment Research cut shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Finally, Cantor Fitzgerald began coverage on shares of Veru in a report on Monday, July 1st. They issued an “overweight” rating and a $6.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $21.00.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Story: How does a margin account work?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.